NCT02355106已完成不适用
A Prospective, Multicenter, Investigation of the Adagio PolarStar System in Subjects With Atrial Flutter
Adagio Medical3 个研究点 分布在 2 个国家目标入组 17 人开始时间: 2015年1月最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 3
- 主要终点
- Safety measured by the percentage of subjects experiencing cardiovascular specific adverse events (CSAE) within thirty 30 days of the ablation procedure.
研究概览
简要总结
The objective of the study is to demonstrate the safety and feasibility of the Adagio System in subjects with Atrial Flutter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Two symptomatic episodes of typical AFl (or chronic atrial flutter) during the one-year period prior to enrollment. This may include typical AFl occurring while receiving anti-arrhythmic drug (AAD) therapy for non-AFl tachyarrhythmia, including atrial fibrillation (AF).
- •At least one episode of typical (clockwise or counterclockwise) atrial flutter documented by 12 lead electrocardiogram (ECG) within 6 months prior to enrollment.
- •Subject has been diagnosed with symptomatic AFl
- •Subject is at least 18 and ≤75 years of age.
- •Subject is able and willing to give informed consent
排除标准
- •Intra-cardiac thrombus has not been eliminated in subjects exposed to less than 4 weeks of therapeutic anticoagulation and a TEE (trans-esophageal echocardiogram) and/or CT did not conclusively rule out thrombus
- •Subject developed persistent AF at least once in history (electrical or pharmacological cardioversion after 48h or episode duration >7 days).
- •Subject had any previous left atrial ablation.
- •Subject had any previous cardiac surgery, e.g. prosthetic valves, except in the case of an isolated coronary bypass surgery performed more than three months prior to the procedure.
- •Subject has permanent pacemaker or defibrillator implant.
- •Subject has 2° type II, 3° degree atrioventricular (AV) block or left/right bundle branch block pattern
- •Subject has unstable angina pectoris.
- •Subject has history of previous myocardial infarction (MI) or percutaneous intervention during the last three months or planned in the next 3 months.
- •Subject has symptomatic carotid stenosis.
- •Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.
- •Subject has any contraindication for oral anticoagulation.
- •Subject has any history of previous transient ischemic attack (TIA) or stroke.
- •Subject has known intra-cardiac thrombus formation.
- •Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).
- •Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.
- •Subject has hypertrophic cardiomyopathy.
- •Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.
- •Subject has sarcoidosis.
- •Subject has myxoma.
- •Subject has thrombocytosis (platelet count > 600,000 / μl) or thrombocytopenia (platelet count <100,000 / μl).
- •Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.
- •Subject has renal dysfunction with glomerular filtration rate < 60 ml/min/1.72m
- •Subject has a reversible causes for AF like alcoholism.
- •Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of randomization) or sterile woman can be enrolled.
- •Subject is a breastfeeding woman.
- •Subject has an active systemic infection.
- •Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer requiring ongoing in-hospital treatment, severe bleeding in history or a suspected pro-coagulant state.
- •Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.
- •Subject has a life expectancy of ≤ 1 year.
- •Subject is participating in any other clinical study
研究组 & 干预措施
Treatment
Experimental
Atrial flutter Ablation
干预措施: PolarStart System (Device)
结局指标
主要结局
Safety measured by the percentage of subjects experiencing cardiovascular specific adverse events (CSAE) within thirty 30 days of the ablation procedure.
时间窗: 30 DAYS
次要结局
- Acute Success measured by Percentage of subjects with termination of AFl and complete bidirectional conduction block across the subeustachian (cavo-tricuspid) isthmus at the end of the ablation procedure.(30 minutes)
- Outcome success(30 days)
研究者
研究点 (3)
Loading locations...
相似试验
尚未招募
2 期
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine TumorsNeuroendocrine TumorsNCT06764368Beijing Chest Hospital39
已完成
不适用
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)Primary Open Angle Glaucoma (POAG)NCT02434692Implandata Ophthalmic Products GmbH24
已完成
1 期
Safety and Performance of the CAVU Medical, Inc. Attune Tubing StudyObesityNCT01422941Cavu Medical, Inc.40
终止
3 期
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)HIV InfectionNCT00443703Merck Sharp & Dohme LLC352
终止
3 期
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)HIV InfectionNCT00443729Merck Sharp & Dohme LLC355